ArticleBlood advances2024

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML.

Jan Philipp Bewersdorf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.